← Eichor
Study identifier: NCT05421416 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Loratadine for the Prevention of G-CSF-related Bone Pain

Condition: Stem Cell Transplant Complications  ·  Sponsor: AHS Cancer Control Alberta

PhasePhase 2
Planned participants78
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.

This description comes directly from the study's public registry record.

Talk to the study team

Michael Chu, MD  ·  780-432-8757  ·  Michael.Chu@ahs.ca

Rammy Khadour  ·  780-432-8795  ·  Rammy.Khadour@ahs.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Cross Cancer InstituteEdmonton, Alberta, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05421416